Urge Incontinence: Clinical Trials

11 trials for Urge Incontinence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 not yet recruiting, 1 recruiting, 1 unknown. 11 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 411Completed 6, Not yet recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1

Follow Urge Incontinence: new trials by email Literature Review of Urge Incontinence trials Research Report on Urge Incontinence

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections
Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask - Overactive Bladder, Neurogenic Bladder
Phase 4Not yet recruitingTriHealth Inc.962026-02-012026-02-04
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Low intensity shockwave therapy, Oral Solifenacin succinate 5 mg - Overactive Bladder (OAB), Urge Incontinence
Phase 4RecruitingMansoura University702025-11-112026-03-16
Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections
Lidocaine 2% without vessel constrictor - Overactive Bladder, Overactive Bladder Syndrome
Phase 4Not yet recruitingUniversity of Louisville362024-12-012024-11-19
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
Single-Dose Antibiotic, Multi-Dose Antibiotic - Overactive Bladder, Overactive Bladder Syndrome
Phase 4CompletedThe Cleveland Clinic1002022-12-062024-01-02
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
OnabotulinumtoxinA 100 UNT [Botox] - Overactive Bladder, Urinary Urge Incontinence
Phase 4CompletedUniversity of California, Irvine1162022-05-012026-02-25
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
mirabegron - Urge Incontinence, Overactive Bladder (OAB)
Phase 4CompletedAstellas Pharma China, Inc.2492021-01-062024-11-15
Minimizing Pain During Office Intradetrussor Botox Injection
Bicarbonate protocol, Standard protocol - Overactive Bladder, Overactive Detrusor
Phase 4CompletedBoston Urogynecology Associates852020-08-152025-03-06
Oral vs Intravesical Analgesia for Office Bladder Botox Injections
Phenazopyridine, Lidocaine 2% Injectable Solution - Overactive Bladder Syndrome, Urge Incontinence
Phase 4UnknownWomen and Infants Hospital of Rhode Island1102018-11-012020-05-29
Treatment of Incontinence Without Memory Problems
Mirabegron, Tolterodine Tartrate - Urge Incontinence, Urinary Incontinence, Urge
Phase 4CompletedUniversity of California, San Francisco232016-02-012019-04-16
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
solifenacin succinate, placebo - Urinary Urge, Urge Incontinence
Phase 4WithdrawnStamford Hospital2008-11-012016-12-06
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
Solifenacin succinate, Simplified bladder training - Overactive Bladder, Urinary Incontinence
Phase 4CompletedAstellas Pharma Inc6432006-05-012014-09-18

Narrower conditions

Urinary Incontinence, Urge (11)  ·  Urinary Bladder, Overactive (10)  ·  Urinary Incontinence (3)  ·  Urinary Bladder, Neurogenic (2)  ·  Agnosia (1)  ·  Pain (1)  ·  Pelvic Floor Disorders (1)  ·  Spasm (1)

Broader conditions

Female Urogenital Diseases (11)  ·  Female Urogenital Diseases and Pregnancy Complications (11)  ·  Lower Urinary Tract Symptoms (11)  ·  Male Urogenital Diseases (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Signs and Symptoms (11)  ·  Urination Disorders (11)  ·  Urogenital Diseases (11)  ·  Urologic Diseases (11)  ·  Urological Manifestations (11)  ·  Urinary Bladder Diseases (10)  ·  Urinary Incontinence (8)  ·  Nervous System Diseases (3)  ·  Neurologic Manifestations (3)  ·  Neurobehavioral Manifestations (1)

Interventions

Lidocaine (3)  ·  Solifenacin Succinate (3)  ·  mirabegron (2)  ·  AIEOP acute lymphoblastic leukemia protocol (1)  ·  Anti-Bacterial Agents (1)  ·  Antibiotic Prophylaxis (1)  ·  Botulinum Toxins, Type A (1)  ·  Nitrous Oxide (1)  ·  Oxygen (1)  ·  Phenazopyridine (1)  ·  Standard of Care (1)  ·  Tolterodine Tartrate (1)  ·  onabotulinum toxin A (1)

Sponsors

Astellas Pharma China, Inc. (1)  ·  Astellas Pharma Inc (1)  ·  Boston Urogynecology Associates (1)  ·  Mansoura University (1)  ·  Stamford Hospital (1)  ·  The Cleveland Clinic (1)  ·  TriHealth Inc. (1)  ·  University of California, Irvine (1)  ·  University of California, San Francisco (1)  ·  University of Louisville (1)  ·  Women and Infants Hospital of Rhode Island (1)

Countries

United States (8)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Egypt (1)  ·  France (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Russia (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

Carly Crowder, MD (1)  ·  Emily Slopnick, MD (1)  ·  Felicia Lane, MD (1)  ·  Lauren E Stewart, MD (1)  ·  Leslee Subak, MD (1)  ·  Sean Francis, MD (1)  ·  Taylor Brueseke, MD (1)

Results publications

PMID 35580634, PMID 37811598, PMID 40025238